13F Holdings
中文EN

RDGL VIVOS INC

Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1449349 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY392.2%
TTM net income YoY-27.1%
TTM EPS YoY-100.0%
Revenue 3-yr CAGR69.3%
Net income 3-yr CAGR—

Margins

Gross margin6.8%
Operating margin-2,414.0%
Net margin-3,032.9%
FCF margin—
EBITDA margin—

Returns

ROE-180.2%
ROA-167.1%
ROIC (approx.)-2,040.3%
Asset turnover0.06x

Leverage & solvency

Liabilities / assets9.7%
Debt / equity0.00x
Current ratio12.33x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.60x
Accruals ratio-66.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$68,379$27,995$19,500$36,499$14,887
Cost of revenue$128,134$30,979$25,536$28,779$12,000
Gross profit-$59,755-$2,984-$6,036$7,720$2,887
R&D expense$352,232$324,629$732,698$343,802$286,848
SG&A expense$296,556$241,824$165,773$151,111$112,037
Operating income-$3.17M-$2.60M-$2.79M-$2.52M-$2.50M
Interest expense————$25,375
Pretax income-$3.07M-$2.91M-$2.89M-$2.47M-$2.53M
Income tax————$0
Net income-$3.07M-$2.91M-$2.89M-$2.47M-$2.53M
EBITDA-$3.16M————
EPS (basic)-0.01-0.01-0.01-0.01-0.01
EPS (diluted)-0.01-0.01-0.01-0.01-0.01
Weighted avg. shares (diluted)452.72M409.67M368.81M351.43M—
Banking
Net interest income$99,030$74,936$49,577——
Balance sheet
Cash & equivalents$1.56M$2.21M$1.59M$1.71M$1.61M
Receivables$22,331$10,326$7,000$11,000—
Inventory$57,257————
Current assets$1.65M$2.23M$1.61M$1.74M$1.63M
PP&E, net$102,811————
Intangibles————$14,000
Total assets$1.87M$2.23M$1.61M$1.74M$1.63M
Current liabilities$117,892$86,209$245,004$81,692$166,915
Total liabilities$206,743$86,209$245,004$81,692$166,915
Shareholders' equity$1.66M$2.15M$1.37M$1.66M$1.47M
Shares outstanding455.49M440.87M387.89M362.54M343.53M
Cash flow statement
Operating cash flow-$2.06M-$1.68M-$1.29M-$1.12M-$963,819
Capital expenditure$103,185————
Free cash flow-$2.16M————
Investing cash flow-$103,185————
Financing cash flow$1.51M$2.30M$1.18M$1.22M$1.67M
Depreciation & amortization$374————
Stock-based compensation————$1.61M

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.